BioMérieux’s New CE-Marked Mass Spectrometry System Makes Lab Life Easier During COVID-19 Pandemic
|
By LabMedica International staff writers Posted on 10 May 2021 |

Image: VITEK MS PRIME (Photo courtesy of BioMérieux)
BioMérieux (Marcy-l'Étoile, France) has announced the CE-marking of VITEK MS PRIME, the next generation of the VITEK MS MALDI-TOF1 mass spectrometry system for routine microbial identification in minutes that aims to make lab life easier during the COVID-19 pandemic.
Rapid microorganism identification is a pivotal step in the microbiology workflow. Over the past decade, Matrix-Assisted Laser Desorption Ionization Time of Flight (MALDI-TOF) mass spectrometry has transformed this process, providing critical information rapidly to clinicians in order to prescribe more effective antimicrobial therapy. Including time-saving innovations to deliver faster identification results, VITEK MS PRIME is a compact benchtop system designed to increase laboratory productivity for greater impact to patient care.
VITEK MS PRIME is a Matrix-Assisted Laser Desorption Ionization Time of Flight (MALDI-TOF) mass spectrometer that analyzes material from microbial cultures to provide microorganism identification. Samples are submitted to multiple laser shots inside VITEK MS PRIME. The matrix absorbs the laser light and vaporizes, along with the sample, in the process gaining an electrical charge (ionization). Electric fields then guide the ions into a vacuum tube which separates them according to their weight, with the smaller molecules rising up the column faster than the larger molecules. This “time of flight” creates a series of peaks, which correspond with the different molecules contained in the organism from the sample. All of these peaks create spectra unique to that microorganism. By comparing the spectra to a vast comprehensive library owned by bioMérieux, the precise microorganism can be identified quickly and easily. VITEK MS PRIME has been designed to incorporate additional benefits to further enhance the use of the MALDI-TOF technology.
With 700,0002 deaths worldwide annually, antimicrobial resistance (AMR) is a global health priority. Antimicrobial Stewardship (AMS), a key part of the arsenal to fight resistance, starts with diagnostics. VITEK MS PRIME positively impacts stewardship programs by providing even faster, highly accurate pathogen identification making excellent use of the large database of clinically relevant species to support earlier, targeted therapy.
“We had extensive input directly from labs as we developed VITEK MS PRIME,” said François Lacoste, Executive Vice President R&D. “The system incorporates numerous innovative features to make lab life easier, including improved automation and serviceability, with a robust database that is consistently expanding with new emerging pathogens and clinically relevant species. It integrates seamlessly with VITEK 2 for antimicrobial susceptibility testing and MYLA middleware for data integration and insights.”
“We are really pleased to bring this unique system to labs during the COVID-19 pandemic, when their needs for optimal workflow and efficiency are greater than ever,” said Pierre Boulud, Chief Operating Officer, Clinical Operations, “VITEK MS PRIME is a powerful innovation that reinforces our offer to support antimicrobial stewardship. Unique features like prioritization of urgent samples and continuous ‘load and go’ allow for greater efficiency and improved outcomes, which are also key in the fight against antimicrobial resistance.”
Related Links:
BioMérieux
Rapid microorganism identification is a pivotal step in the microbiology workflow. Over the past decade, Matrix-Assisted Laser Desorption Ionization Time of Flight (MALDI-TOF) mass spectrometry has transformed this process, providing critical information rapidly to clinicians in order to prescribe more effective antimicrobial therapy. Including time-saving innovations to deliver faster identification results, VITEK MS PRIME is a compact benchtop system designed to increase laboratory productivity for greater impact to patient care.
VITEK MS PRIME is a Matrix-Assisted Laser Desorption Ionization Time of Flight (MALDI-TOF) mass spectrometer that analyzes material from microbial cultures to provide microorganism identification. Samples are submitted to multiple laser shots inside VITEK MS PRIME. The matrix absorbs the laser light and vaporizes, along with the sample, in the process gaining an electrical charge (ionization). Electric fields then guide the ions into a vacuum tube which separates them according to their weight, with the smaller molecules rising up the column faster than the larger molecules. This “time of flight” creates a series of peaks, which correspond with the different molecules contained in the organism from the sample. All of these peaks create spectra unique to that microorganism. By comparing the spectra to a vast comprehensive library owned by bioMérieux, the precise microorganism can be identified quickly and easily. VITEK MS PRIME has been designed to incorporate additional benefits to further enhance the use of the MALDI-TOF technology.
With 700,0002 deaths worldwide annually, antimicrobial resistance (AMR) is a global health priority. Antimicrobial Stewardship (AMS), a key part of the arsenal to fight resistance, starts with diagnostics. VITEK MS PRIME positively impacts stewardship programs by providing even faster, highly accurate pathogen identification making excellent use of the large database of clinically relevant species to support earlier, targeted therapy.
“We had extensive input directly from labs as we developed VITEK MS PRIME,” said François Lacoste, Executive Vice President R&D. “The system incorporates numerous innovative features to make lab life easier, including improved automation and serviceability, with a robust database that is consistently expanding with new emerging pathogens and clinically relevant species. It integrates seamlessly with VITEK 2 for antimicrobial susceptibility testing and MYLA middleware for data integration and insights.”
“We are really pleased to bring this unique system to labs during the COVID-19 pandemic, when their needs for optimal workflow and efficiency are greater than ever,” said Pierre Boulud, Chief Operating Officer, Clinical Operations, “VITEK MS PRIME is a powerful innovation that reinforces our offer to support antimicrobial stewardship. Unique features like prioritization of urgent samples and continuous ‘load and go’ allow for greater efficiency and improved outcomes, which are also key in the fight against antimicrobial resistance.”
Related Links:
BioMérieux
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
Rapid Ferritin Test Enables Iron Deficiency Detection at the Point of Care
Iron deficiency is one of the world’s most common nutritional disorders and can be difficult to diagnose where access to laboratories and trained personnel is limited. Women and children in low-resource... Read more
Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40
C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read moreMolecular Diagnostics
view channel
Genetic Risk Score Identifies Type 1 Diabetes in MODY Testing
Accurately distinguishing maturity-onset diabetes of the young from type 1 diabetes is difficult in routine care, especially when onset occurs in adolescence or early adulthood. Although maturity-onset... Read more
Self-Collected HPV Testing Reaches Patients Missed by Routine Screening
Timely cervical cancer screening prevents progression from persistent high‑risk human papillomavirus (HPV) infection, yet many adults marginalized from care do not complete routine exams.... Read more
Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers
Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read morePathology
view channel
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
Glioma surgery depends on distinguishing infiltrative tumor from functional brain tissue, but microscopic spread beyond visible margins makes this difficult. Conventional frozen sections provide rapid... Read moreTechnology
view channel
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read moreIndustry
view channel
AI-Powered Pathology Collaboration Supports Companion Diagnostic Development
Imagene AI has joined the Proscia Ready partner alliance to integrate its hematoxylin and eosin (H&E) screening tools and immunohistochemistry (IHC) image-analysis capabilities with Proscia’s Concentriq... Read more








